Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/8/2019
SIETES contiene 92796 citas

 
 
 1 a 13 de 13 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 2017;83:2148-62. [Ref.ID 102081]
2. Cita con resumen
Anónimo. NICE endorses bosutinib for treatment of myeloid leukemia. DIA Daily 2016:3. [Ref.ID 100484]
5.Enlace a cita original Cita con resumen
Hawkes N. NHS England drops 16 medicines from Cancer Drugs Fund. BMJ 2015;351:h4803. [Ref.ID 99469]
6. Cita con resumen
Anónimo. Britain’s NHS cuts funding for costly cancer medicines. DIA Daily 2015:13 de enero. [Ref.ID 98704]
7. Cita con resumen
Anónimo. Bosutinib. Prescrire 2014;34:10. [Ref.ID 97006]
8.Tiene citas relacionadas
Doroshow JH. Overcoming resistance to targeted anticancer drugs. N Engl J Med 2013;369:1852-3. [Ref.ID 96519]
9.Tiene citas relacionadas
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Godlman JM, Shah NP, Kantarjian H, PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369:1783-96. [Ref.ID 96515]
10.Tiene citas relacionadas Cita con resumen
Groarke JD, Cheng S, Moslehi J. Cancer-drug discovery and cadiovascular surveillance. N Engl J Med 2013;369:1779-81. [Ref.ID 96514]
11. Cita con resumen
Shah R, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf 2013;36:491-503. [Ref.ID 95770]
12.
Shah DR, Shah RR, Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Saf 2013;36:413-26. [Ref.ID 95664]
13.
Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf 2013;36:295-316. [Ref.ID 95517]
Seleccionar todas
 
 1 a 13 de 13